Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 10;13(4):594-607.
doi: 10.3390/neurolint13040059.

Benzodiazepines: Uses, Dangers, and Clinical Considerations

Amber N Edinoff  1 , Catherine A Nix  1 , Janice Hollier  1 , Caroline E Sagrera  2 , Blake M Delacroix  2 , Tunde Abubakar  2 , Elyse M Cornett  3 , Adam M Kaye  4 , Alan D Kaye  3
Affiliations
Review

Benzodiazepines: Uses, Dangers, and Clinical Considerations

Amber N Edinoff et al. Neurol Int. .

Abstract

Benzodiazepines (BZDs) are among one of the most widely prescribed drug classes in the United States. BZDs are a class of psychoactive drugs known for their depressant effect on the central nervous system (CNS). They quickly diffuse through the blood-brain barrier to affect the inhibitory neurotransmitter GABA and exert sedative effects. Related to their rapid onset and immediate symptom relief, BZDs are used for those struggling with sleep, anxiety, spasticity due to CNS pathology, muscle relaxation, and epilepsy. One of the debilitating side effects of BZDs is their addictive potential. The dependence on BZDs generally leads to withdrawal symptoms, requiring careful tapering of the medication when prescribed. Regular use of BZDs has been shown to cause severe, harmful psychological and physical dependence, leading to withdrawal symptoms similar to that of alcohol withdrawal. Some of these withdrawal symptoms can be life threatening. The current treatment for withdrawal is through tapering with clonazepam. Many drugs have been tested as a treatment for withdrawal, with few proving efficacious in randomized control trials. Future research is warranted for further exploration into alternative methods of treating BZD withdrawal. This call to action proves especially relevant, as those seeking treatment for BZD dependence and withdrawal are on the rise in the United States.

Keywords: GABA; benzodiazepines; cognitive decline; withdrawal.

PubMed Disclaimer

Conflict of interest statement

None of the authors have any conflict of interest to report in this project.

References

    1. Griffin C.E., Kaye A.M., Bueno F.R., Kaye A.D. Benzodiazepine Pharmacology and Central Nervous System–Mediated Effects. Ochsner J. 2013;13:214–223. - PMC - PubMed
    1. Campo-Soria C., Chang Y., Weiss D.S. Mechanism of action of benzodiazepines on GABAA receptors. Br. J. Pharmacol. 2006;148:984–990. doi: 10.1038/sj.bjp.0706796. - DOI - PMC - PubMed
    1. Louvet S., Ischayek M., Danoff R. The current role of long-term benzodiazepines for the treatment of generalized anxiety. Osteopath. Fam. Physician. 2015;7:19–25. doi: 10.1016/ofp.v7i1.364. - DOI
    1. Susman J., Klee B. The role of high-potency benzodiazepines in the treatment of panic disorder. Prim. Care Companion J. Clin. Psychiatry. 2005;7:5–11. doi: 10.4088/PCC.v07n0101. - DOI - PMC - PubMed
    1. Fluyau D., Revadigar N., Manobianco B.E. Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Ther. Adv. Psychopharmacol. 2018;8:147–168. doi: 10.1177/2045125317753340. - DOI - PMC - PubMed

LinkOut - more resources